InspireMD, Inc. (NSPR)

Develops medical devices for cardiovascular diseases, focusing on stent systems and innovative solutions.

NSPR Stock Quote

Company Report

InspireMD, Inc. operates as a leading medical device company specializing in the advancment and commercialization of its proprietary MicroNet stent platform technology. Focused primarily on treating vascular and coronary diseases, the company distributes its innovative products across Europe, Latin America, the Middle East, and the Asia Pacific regions. InspireMD's product portfolio includes the CGuard carotid embolic prevention system, designed for carotid artery applications, and the MGuard Prime embolic protection systems, tailored for patients with acute coronary syndromes such as acute myocardial infarction and saphenous vein graft coronary interventions, along with applications in bypass surgery. Additionally, the company is actively developing PVGuard, a MicroNet mesh sleeve integrated with a self-expandable stent aimed at peripheral vascular treatments.

InspireMD, Inc. engages in sales through a network of local distributors, facilitating broad accessibility to its innovative medical technologies worldwide. Originally founded in 2005 and headquartered in Tel Aviv-Yafo, Israel, InspireMD continues to drive forward its commitment to improving patient outcomes through cutting-edge research and development. The company's dedication to advancing vascular health solutions underscores its leadership in the global medical device industry.

With a strong emphasis on technological innovation and clinical efficacy, InspireMD remains at the forefront of developing next-generation stent technologies. By collaborating closely with healthcare providers and strategic partners, the company strives to expand its market presence and enhance the standard of care for patients facing complex cardiovascular challenges.

NSPR EPS Chart

NSPR Revenue Chart

Stock Research

EFT JELD BP BGCP JBI ICHR HALO

NSPR Chart

View interactive chart for NSPR

NSPR Profile

NSPR News

Analyst Ratings